Background: Statins (3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors) consumption provides beneficial effects on cardiovascular systems. However, effects of statins on vascular K ATP channel gatings are unknown.
Introduction
3-Hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase is a 97-kDa glycoprotein embedded in the endoplasmic reticulum [1] which is involved in the endogenous cholesterol biosynthesis in mammalian liver and intestine [2] . Pervious study of our group [3] has clearly illustrated the biochemical existence of extra-hepatic HMG-CoA reductase in human and porcine cardiovascular tissues, suggesting a physiological role of this enzyme in the cardiovascular system. HMG-CoA reductase inhibitors, commonly known as statins, have been shown to be an effective treatment of hypercholesterolemia and cardiovascular diseases via its cholesterol-lowering property and cholesterolindependent effects (pleiotropic effects) [3, 4, 5, 6, 7, 8] .
Regulation of vascular tone relies on complex cellular mechanisms as well as the opening and closing of various ion channels. Previous studies have demonstrated that statins can modify the activities of different ion channels in blood vessels including L-type Ca 2+ channel and BK Ca channel [3, 9, 10, 11] . In addition to Ca 2+ channels and BK Ca channels, ATP-sensitive K + (K ATP ) channels are abundant in vascular tissues and K ATP channels are also important in regulating the vascular tone [12] . In rat isolated aorta, cerivastatin-induced a glibenclamide (a K ATP channel blocker)-sensitive aortic relaxation [13] and pravastatin reduced myocardial infact size through opening of mitochondrial K ATP channels in rabbit [14] . However, a recent study reported that simvastatin, but not pravastatin, inhibited pinacidil (a K ATP channel opener)-induced relaxation of pig's isolated coronary arteries suggesting that different statins have differential effects on K ATP channels of different cells/tissues [40] .
Similar to other ion channels, the opening and closing of K ATP channels are modulated by multiple cell signaling mechanisms, such as phosphorylation by protein kinase A (PKA) [15] , protein kinase C (PKC) [16] and cGMP-dependent protein kinase (PKG) [17] . In addition, the intracellular ATP level is an essential determinant of K ATP channel gatings. It is well-known that AMPactivated protein kinase (AMPK) serves as a 'metabolic master regulator' which is sensitive to changes of intracellular AMP/ATP ratio. Activation of AMPK results in suppression of intracellular energy-consuming pathways and generation of ATP i.e. an increase in cellular ATP level. In mouse isolated pancreatic islets, activation of AMPK by AICAR (an AMPK activator) potentiated insulin secretion by inhibiting K ATP channel openings [18] . Moreover, phenformin (another AMPK activator), inhibited K ATP channel openings in mouse aortic smooth muscle cells [19] , highlighting the participation of AMPK activity in K ATP channel gatings in VSMC. Unfortunately, in various ex vivo studies (multicellular preparations), there is no consensus on the vascular effects mediated by AMPK activation as both contraction and relaxation were observed [20, 21, 22, 23, 24] , and the underlying reason(s) for the discrepancy is unknown. Given the fact that statins promoted phosphorylation of AMPK in human and bovine endothelial cells [25] , it is tempting to suggest that activation of AMPK by simvastatin could modulate vascular K ATP channel gatings and vascular reactivity.
Therefore, in this study we hypothesize that acute simvastatin could modulate vascular K ATP channel gatings and the simvastatin-mediated effects involve activation of AMPK signaling pathway. Thus, in this study, experiments were designed to evaluate the effects of acute simvastatin on vascular K ATP channel gatings of pig's coronary artery, and the participation of AMPK activation.
Materials and Methods

Animal and Human Ethics Statements
This investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). The protocol was approved by the Animal Ethics Committee of the Chinese University of Hong Kong (Approval Number: 10/003/DRG). Permission prior to the collection of fresh pig's heart for research purposes was obtained from Sheung Shui Slaughterhouse (Hong Kong).
Fresh human left internal mammary arteries were the leftover obtained from patients with cardiovascular diseases undergoing coronary artery bypass grafting (CABG) procedures, and the use of human tissues for research purposes was approved by the Human Research Ethics Committee of the Chinese University of Hong Kong (CREC Ref. No. 2006.313) . Written consents were obtained, prior to surgery, from patients voluntarily involved for the usage of tissues solely for research purposes. Patients had read and understood the patient information document provided, and the aims and methods of this study had been fully explained to them. Patients involved had given written informed consent (as outlined in PLOS consent form) to authors of this manuscript for publication of these data.
Isometric Tension Measurement
Fresh hearts were obtained from pigs (,35 kg) that were slaughtered in the morning of the experiment at a local slaughterhouse. The heart was immediately immersed in an icecold physiological salt solution. Segment of the left anterior descending (LAD) coronary artery (tertiary branch, O.D. ,500-800 mm) was dissected within an hour after the animal was slaughtered.
Fresh human left internal mammary arteries were bathed in an ice-cold physiological salt solution before transported to the laboratory from the operation theatre of the Prince of Wales Hospital (Hong Kong) within an hour. Fat and connective tissues were carefully removed under the dissecting stereo-microscope.
Arterial rings (porcine coronary artery and human internal mammary artery) (endothelium was removed using a blunted watch-maker forceps) were bathed in a 5-ml thermo-regulated wire myograph contained physiological salt solution with the composition (mM): NaCl 118.3, KCl 4.6, MgSO 4 1.2, NaHCO 3 25, KH 2 PO 4 1.2, CaCl 2 2.5, and glucose 11 (bubbled with 16%O 2 /5%CO 2 balanced with N 2 , pO 2 = ,100 mmHg). Rings (1 mm in length) were equilibrated under resting tension of 1 g [26, 27] using two stainless steel wires (diameter ,100 mm), in the bath solution for 90 min. Resting tension was re-adjusted, if necessary, before commencing the experiments. The reason for choosing these tissues in this study is because previous reports demonstrated the existence of K ATP channels in these vascular tissues [28, 29] .
Enzymatic Dissociation of Myocytes
Porcine left anterior descending coronary artery myocytes and human left internal mammary artery myocytes were dissociated using collagenase and protease, as reported [3, 13] for conventional whole-cell patch-clamp electrophysiology experiments.
Electrophysiological Measurement of K ATP Gatings
Conventional whole-cell, patch-clamp experiments were performed at room temperature (, 22uC) using single-cell, voltageclamp techniques (Axopatch 200B amplifier and Digidata 1200 A/D interface) (Axon Instruments, USA) with recording patch pipettes of 2-4 MV (when filled with internal pipette solution). Whole-cell recording configurations were used so as to maintain a ''pre-determined concentration'' of ATP (i.e. 1 mM) inside all the cells used during the recording of K ATP channels for a fair/accurate comparison of K ATP channel gatings of different cells (pig coronary artery and human internal mammary artery) in response to drug challenges. In addition, this mode of recording offers the convenience of a rapid delivery of drugs (e.g. simvastatin Na [15] . The cell was held at 0 mV, and pulse voltages from -100 to +40 mV with a 20-mV increment (with pulse duration of 1 s, stimulated at 0.1 Hz) were applied. Current records were low-pass filtered, digitized and stored on computer hard-disk for later analysis using the Clampfit 9 softwares (Axon Instruments, USA).
Confocal Laser Scanning Microscopy
Porcine coronary artery myocytes were incubated with Fluo-4/ AM (5 mM in 0.05% DMSO) (60 min, 37uC) in HEPES buffer (mM): NaCl 140, KCl 5, MgCl 2 1, CaCl 2 1, glucose 10, and HEPES 10 (pH 7.4). After washing, myocytes were imaged using an Eclipse CL Plus Confocal Microscope System (Nikon, Japan) with an excitation at 488 nm and a band-pass filter at 515/ 530 nm. Fluorescence changes of myocytes (at room temperature) in response to drugs (simvastatin (10 mM) and AICAR (1 mM), with and without ryanodine (100 mM)) were acquired at 15-s intervals. Images were recorded and analyzed by software EZ-C1 3.5 (Nikon, Japan). ]-2-Deoxy-glucose uptake into porcine coronary artery myocytes was determined using previously described protocols with minor modifications [30] . All experiments were performed in HEPES-buffered Ringer's solution containing (mM): NaCl 135; KCl 5; NaH 2 PO 4 3.33; Na 2 HPO 4 0.83; CaCl 2 1.0; MgCl 2 1.0 and HEPES 5 (pH 7.4). Confluent monolayer of cultured porcine coronary artery myocytes in 24-well plates were washed three times in Ringer's solution. [ 3 H]-2-Deoxy-glucose (10 mM, 4 mCi/ ml) was added to each well and incubated for 30 min (37uC). The plates were then washed three times rapidly with ice-cold phosphate-buffered saline before cells were solubilized in 0.5 ml of Triton X-100 (5% vol./vol.). To determine non-specific uptake of [
Measurement of [Glucose] o Uptake
Determination of Cellular ATP Contents
ATP was extracted from cultured porcine coronary artery myocytes (before and after drug treatments) by trichloroacetic acid (final concentration, 0.5% vol./vol.). Trichloroacetic acid in the sample was then neutralized and diluted to a final concentration of 0.1% by adding Tris-acetate buffer (pH 7.75). The ATP content was analyzed using the ATP-dependent luciferin-luciferase bioluminescence assay (ENLITENH ATP assay system, Promega, USA).
Western Immunoblots
Isolated porcine coronary artery and human internal mammary artery (both were endothelium denuded) were homogenized in the presence of protease inhibitors (Roche, USA) to obtain extracts of proteins. Protein concentrations were determined using BCA TM protein assay kit (Pierce, USA). Samples (40 mg of protein per lane) were loaded onto a 10% SDS-polyacrylamide electrophoresis gel. After electrophoresis (90 V, 120 min), the separated proteins were transferred (12 mA, 45 min) to polyvinylidene difluoride membrane (Bio-Rad, USA). Non-specific sites were blocked with 5% non-fat dry milk (Bio-Rad, USA) for 120 min, and the blots were then incubated with individual type of antibody: anti-HMG CoA reductase, 1:1,000 (Upstate Biotechnology, USA); anti-p-HMG CoA reductase-Ser 871 , 1:1,000 (Kinasource, UK); anti-CYP450 3A4, 1:1,000 (Affinity Bioreagent, USA); anti-PP2A, 1:1,000 (Upstate Biotechnology, USA); anti-p-PP2A-Tyr 307 , 1:1,000 (Upstate Biotechnology, USA); anti-AMPK, 1:1,000 (Upstate Biotechnology, USA), anti-p-AMPKa-Thr 172 , 1:1,000 (Upstate Biotechnology, USA); anti-LKB1, 1:1,000 (Upstate Biotechnology, USA) and anti-p-LKB1-Ser 428 , 1:1,000 (Upstate Biotechnology, USA) overnight at 4uC. Anti-mouse HRP conjugated IgG, 1:1,000 (Bio-Rad, USA) or anti-rabbit HRP conjugated IgG, 1:1,000 (BioRad, USA) was used to detect the binding of the corresponding antibody. Membranes were stripped and re-blotted with anti-bactin antibody, 1:10,000 (Sigma-Aldrich, USA) to verify an equal loading of protein in each lane. The protein expression was detected with ImmueStar Reagent (Bio-Rad, USA) and quantified using Scion Image analysis programme (Scion Image Ltd., USA).
Chemicals
Simvastatin, cromakalim, glibenclamide, AICAR, compound C, rottlerin, ryanodine, caffeine, U46619, KB R-7953 mesylate, H89 dihydrochloride, okadaic acid, KN93 and KN92 were purchased from Tocris Biosciences (UK). Simvastatin Na + (50 mmol/L) was prepared from simvastatin using NaOH (in ethanol), as suggested by the manufacturer (Tocris Biosciences, UK). Nifedipine, D-mannitol, pinacidil, ouabain, phloridzin, 5-(Nethyl-N-isopropyl) amiloride (EIPA), N-methyl-D-glucamine chloride and ketoconazole were obtained from Sigma-Aldrich (USA).
Statistical Analysis
All data were obtained from at least 6 independent experiments. Statistical analysis was performed using Student's t test or ANOVA (one-way or two-way), where appropriate. A P value of ,0.05 was considered significant. Data are expressed as mean 6 S.EM.
Results
Biochemical Existence of HMG-CoA Reductase and the Effects of Simvastatin and Simvastatin Na
+ on HMG-CoA Reductase Expression
The biochemical existence of HMG CoA reductase was determined in both human isolated left internal mammary artery and porcine isolated coronary artery. Porcine liver served as the positive control. Western blot results confirmed the biochemical existence of HMG-CoA reductase in both human and porcine vascular preparations. Beta actin was used as a loading control ( Figure 1A ).
We then investigated the effects of simvastatin and simvastatin Na + in inhibiting HMG CoA reductase activity (i.e. phosphorylation of HMG CoA reductase) [29] . Neither simvastatin nor simvastatin Na + (10 mM, incubation # 30 min) altered the protein expression of p-HMG-CoA reductase-Ser 871 and HMG-CoA reductase in porcine isolated coronary artery ( Figure 1B ).
Effects of Simvastatin on K ATP Channel Opener-induced Relaxation
To evaluate the involvement of K ATP channels, effects of simvastatin on K ATP channel opener-mediated vascular relaxation were examined. Cromakalim and pinacidil (both are K ATP channel openers) (10 nM to 10 mM) caused a glibenclamide (1 and 3 mM)-sensitive relaxation of U46619 (10 nM) pre-constricted coronary artery (endothelium-denuded) relaxation in a concentration-dependent manner (data not shown). Glibenclamide alone did not alter the basal tension and U46619-induced contraction. Simvastatin (3 and 10 mM), but not simvastatin Na + (1, 3 and 10 mM), significantly attenuated cromakalim-and pinacidilinduced relaxation (Figure 2A and B) . Neither simvastatin nor simvastatin Na + altered the basal tension of the preparation. Okadaic acid (a potent PP2A inhibitor) was used to elucidate the involvement of PP2A in simvastatin-suppressed cromoakalim-and pinacidil-inudced relaxation. Okadaic acid (10 nM) eradicated simvastatin (10 mM)-induced inhibition of cromakalim-and pinacidil-induced relaxation (n = 6) ( Figure 2C and D). Okadaic acid (10 nM) alone did not modify cromakalim-induced relaxation.
Effects Simvastatin on K ATP Openings
In order to get a better understanding on the modulation of K ATP channels gatings by simvastatin, experiments were performed in single vascular myocytes. Cromakalim (10 mM) ( Figure 3A ) and pinacidil (10 mM) (data not shown) significantly enhanced the recorded outward K + current amplitude which is inhibited by glibenclamide (a K ATP channel blocker), indicating that the recorded K + current is the genuine K ATP current. In human internal mammary artery myocytes, neither simvastatin (1, 3 and 10 mM) nor simvastatin Na + (1, 3 and 10 mM) altered the basal K ATP channel gatings (data not shown). Interestingly, simvastatin caused a concentration-dependent inhibition of cromakalim (10 mM)-induced K ATP channel opening, with no apparent recovery after washout ( Figure 3B ). However, simvastatin Na + (10 mM, applied either in external bath solution or included in the pipette solution) did not alter cromakalim (10 mM)-induced K ATP opening (data not shown).
Due to the irregular/limited supply of human left internal mammary artery for research purposes, the following experiments were performed using porcine coronary artery myocytes. All drugs/inhibitors were tested against both cromakalim-and pinacidil-induced K ATP opening, however only representative figures of drug modulation of cromakalim-mediated responses were illustrated in the Figures.
Okadaic acid (a potent PP2A inhibitor) was used to examine the involvement of PP2A in simvastatin-mediated suppression of cromakalim-and pinacidil-induced K ATP opening. Okadaic acid (10 nM) did not alter the basal K ATP openings, and cromakalim (10 mM)-and pinacidil (10 mM)-induced K ATP openings. However, okadaic acid (10 nM, in the pipette solution) significantly attenuated simvastatin (10 mM)-mediated suppression of cromakalim (10 mM)-and pinacidil (10 mM)-induced K ATP openings ( Figure 3C ). In contrast, okadaic acid failed to alter glibenclamide (3 mM)-mediated inhibition of cromakalim-and pinacidil-induced K ATP openings ( Figure 3C ).
The involvement of AMPK on cromakalim-and pinacidilinduced K ATP channel openings was examined. Similar to simvastatin (10 mM), AICAR (1 mM, an AMPK activator) attenuated cromakalim-and pinacidil-induced K ATP channel openings ( Figure 3D ). However, AICAR (1 mM) did not alter the basal K ATP amplitude (data not shown).
Effects of Simvastatin on AMPK and PP2A Phosphorylation
To strengthen our hypothesis on the participation of AMPK activation on mediating simvastatin-induced responses, we evaluated AMPK activity using Western blots. Activity of AMPK is represented by p-AMPKa-Thr 172 /total AMPK, as previously demonstrated [31] . AICAR (1 mM) and simvastatin (10 mM) caused a time-dependent (2-30 min) increase of AMPK activation (i.e. increased p-AMPKa-Thr 172 expression) ( Figure 4A and B). These responses were sensitive to Compound C (an AMPK inhibitor) (1 mM; 30 min) ( Figure 4C ). Okadaic acid (10 nM, 30 min) ( Figure 4D ) did not alter simvastatin (10 mM)-mediated increase of AMPK activity.
The role of PP2A activation (represented by p-PP2A-Tyr 307 / total PP2A), as previously reported [32] , in response to simvastatin and AICAR challenges was evaluated using okadaic acid and Compound C. Simvastatin (10 mM) and AICAR (1 mM) elicited a time-dependent (2 to 30 min) increase in p-PP2A-Tyr 307 /total PP2A (i.e. a decreased PP2A activity) ( Figure 5A Figure 6C ). Caffeine (1 mM) caused a time-dependent (2 to 30 min) (ryanodine-sensitive) AMPK activation ( Figure 6D ). Ryanodine, on its own, did not alter AMPK activation.
Ryanodine pre-treatment (100 mM) abolished simvastatin (10 mM)-, AICAR (1 mM) and caffeine (1 mM)-induced changes of p-PP2A-Tyr 307 /total PP2A ( Figure 6E ). Moreover, effects of simvastatin (10 mM)-and caffeine (1 mM)-, but not AICAR (1 mM)-, on PP2A activities were abolished by KN 93 (10 mM) ( Figure 6F ), but not by KN 92 (10 mM) (data not shown). In addition, effects of simvastatin (10 mM) and AICAR (1 mM) on AMPK and PP2A activities were not modified by [Ca 2+ ] o -free solution (with EGTA, 2 mM), KB R-7953 (10 mM)-or nifedipine (10 mM)-containing solutions (data not shown).
Effects Simvastatin and AICAR on [Glucose] o Uptake
In order to establish the role of [glucose] o , effects of simvastatin and AICAR on [glucose] o uptake was determined. Simvastatin (10 mM) and AICAR (1 mM) caused a significant increase in [ Figure 7E ). However, EIPA (10 mM) did not Figure 2 . Effects of simvastatin on K ATP channel openers-induced vasorelaxation. (A) Effect of simvastatin (1, 3 and 10 mM) (n = 6 to 8) on cromakalim-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery (endothelium-denuded). (B) Effect of simvastatin (1, 3 and 10 mM) (n = 6 to 8) on pinacidil-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery (endothelium-denuded). (C) Effect of okadaic acid (10 nM) (n = 6 to 8) on simvastatin-inhibited cromakalim-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery (endothelium-denuded). (D) Effect of okadaic acid (10 nM) (n = 6 to 8) on simvastatin-inhibited pinacidil-induced relaxation of U46619 (10 nM) precontracted porcine coronary artery (endothelium-denuded). *P,0.05, **P,0.01 and ***P,0.001 compared to controls. doi:10.1371/journal.pone.0066404.g002 modify simvastatin (10 mM)-and AICAR (1 mM)-mediated changes of p-PP2A-Tyr 307 /total PP2A (data not shown).
Effects of Simvastatin on [ATP] i Levels and LKB1 Activation
To confirm the generation of [ATP] i after [glucose] o uptake induced by simvastatin, cellular ATP level was estimated in response to drug challenges. AICAR caused a Compound C (10 mM)-sensitive increase in cellular ATP level of the arterial Figure 3 . Effects of simvastatin on K ATP channel openings. (A) Effects of cromakalim (Crom., 10 mM) on whole-cell K ATP channel openings of single human internal mammary artery myocytes in the presence of glibenclamide (Glib., 3 mM) (n = 5 to 6). (B) Effects of cromakalim (Crom., 10 mM) on whole-cell K ATP channel openings of single human internal mammary artery myocytes with and without simvastatin (1, 3 and 10 mM). (C) Effects of simvastatin (10 mM) and glibenclamide (Glib., 3 mM) on cromakalim (Crom., 10 mM)-induced whole-cell K ATP channel openings of single porcine artery myocytes (in the presence of okadaic acid, 10 nM). Number of cells studied is indicated in parenthesis. *P,0.05, **P,0.01 and ***P,0.001 compared to controls. (D) Effects of cromakalim (Crom., 10 mM) on whole-cell K ATP channel openings of single porcine coronary artery myocytes in the presence of AICAR (1 mM). Number of cells studied is indicated in parenthesis. *P,0.05, **P,0.01 and ***P,0.001 compared to controls. doi:10.1371/journal.pone.0066404.g003 myocytes ( Figure 8A ) and a time-dependent (2 to 30 min) increase in LKB1 activity (i.e. an increase in p-LKB1-Ser 428 /total LKB1 [33] ) ( Figure 8B ). However, simvastatin increased intracellular ATP level of the arterial myocytes with no apparent change in p-LKB1/total LKB1 ( Figure 8C ).
Participation of Cytochrome P450 3A4
To elucidate the importance of cytochrome P450 (CYP450)-mediated drug metabolism in mediating simvastatin-induced responses, effects of CYP450 3A4 inhibitor was examined. The biochemical existence of CYP450 3A4 protein was confirmed in porcine coronary artery and human internal mammary artery ( Figure 9A ). Porcine liver served as the positive control. Ketoconazole (10 mM, a selective CYP450 3A4 inhibitor) failed to modify simvastatin (10 mM)-induced changes of AMPK and PP2A activities ( Figure 9B and C).
Discussion
In this study, acute simvastatin (membrane permeable) suppressed cromakalim-and pinacidil-induced relaxation of U46619 pre-constricted (endothelium-denuded) arteries with no effects on basal tension. In single myocytes of porcine coronary artery and human left internal mammary artery, simvastatin and AICAR inhibited cromakalim-and pinacidil-evoked K ATP channel openings with no apparent effect on basal K ATP channel gatings. Thus, a prerequisite opening of K ATP channels (by two structurally different K ATP channel openers cromakalim and pinacidil) is necessary for simvastatin and AICAR to demonstrate K ATP channel blocking properties. However, simvastatin Na + (membrane impermeable) did not alter the cromakalim2/ pinacidil-induced relaxation and the K ATP channel openings. Therefore, these results suggest that the lipophilic property of simvastatin is essential [3, 34] .
Acute application of HMG-CoA reductase inhibitors (pravastatin, atorvastatin and cerivastatin) elicited an endotheliumdependent relaxation of pre-constricted rat isolated aorta, and cerivastatin-induced relaxation was attenuated by glibenclamide and ouabain [13] . Activation of cardiac K ATP channels by statins has been reported [14, 35, 36] . However, a recent study [37] and our current study demonstrated that simvastatin inhibits pinacidilinduced relaxation in porcine isolated coronary artery. Furthermore, our result illustrate that simvastatin consistently suppressed, instead of enhanced, cromakalim-and pinacidil-induced K ATP channel openings of arterial myocytes of pig coronary artery and human left internal mammary artery. Taken together, these results clearly illustrate that simvastatin could alter vasodilatation via the inhibition of K ATP channels.
AMPK (formerly termed HMG-CoA reductase kinase) is activated by an increase in [AMP/ATP] i ratio and a rise in [Ca
2+
] i which signals an increase in energy demands [38, 39] . Once activated, AMPK decreases ATP consumption and/or stimulates ATP production (e.g. via oxidative phosphorylation) and the [ATP] i level is thus restored [40] . In human umbilical vein endothelial cells (HUVECs), atorvastatin activated AMPK [25] whereas in mouse pancreatic islets b-cells, AICAR (an AMPK activator) inhibited K ATP openings [41] . Acute application of simvastatin significantly suppressed vasoconstriction of rat mesenteric resistance arteries via an AMPKa-phosphorylation-dependent mechanism [42] . In addition, AICAR activates AMPK via an increased phosphorylation, and phosphorylation (i.e. inactivation) of a known target for AMPK i.e. HMG-CoA reductase occurred [18, 43, 44] . However, in our study neither simvastatin nor simvastatin Na + (incubation # 30 min) altered the expression of HMG-CoA reductase and p-HMG-CoA reductase-Ser 871 (the inactivated isoform of HMG-CoA reductase) suggesting that AICAR and simvastatin are acting through different cellular mechanisms (see below). In rat's liver, AMPK is associated with HMG-CoA reductase [45] . In our study, simvastatin and AICAR ] i changes in response to simvastatin (10 mM) before and after ryanodine (100 mM) challenges. Results are expressed (Area Under Curve, AUC) as mean 6 SEM of 13-15 cells (***P,0.001). (C) Summary of the effects of ryanodine (100 mM) on simvastatin (10 mM)-or AICAR (1 mM)-induced protein expression of p-AMPK/total AMPK in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (D) Summary of the effects of caffeine (1 mM) on the protein expression of p-AMPK/total AMPK in porcine coronary artery, with and without ryanodine (100 mM). *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (E) Effect of ryanodine (100 mM) on simvastatin (10 mM)-induced protein expression of p-PP2A/total PP2A in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (F) Summary of the effect of simvastatin (10 mM), AICAR (1 mM) and caffeine (1 mM) on the protein expression of p-PP2A/total PP2A, with and without KN93 (10 mM) in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). doi:10.1371/journal.pone.0066404.g006 consistently increased p-AMPKa-Thr 172 expression (i.e. activation) [44] , and suppressed cromakalim-and pinacidil-induced K ATP channel openings. Taken together, our results illustrate that acute simvastatin inhibits vascular K ATP channel openings probably via AMPKa-Thr 172 phosphorylation (i.e. activation). Okadaic acid (a potent PP2A inhibitor), but not rotterlin (a PKC-d inhibitor) or H89 (a PKA inhibitor), reversed the inhibitory effects of simvastatin on cromakalim-and pinacidil-mediated K ATP channel openings strengthen our conclusion on the participation of PP2A. In contrast to cultured bovine aortic endothelial cells (BAECs) [46] , simvastatin-and AICAR-mediated increase in PP2A-Tyr 307 phosphorylation was abolished by Compound C (an AMPK inhibitor) illustrating that PP2A is phosphorylated (i.e. inactivated) in an ''AMPKa-dependent'' manner, and PP2A phosphorylation occurs at a site downstream of AMPKa activation/phosphorylation. In addition, AMPK can be activated via the LKB1 (the upstream serine/threonine kinase of AMPK) cascade [47] . In cultured BAECs, simvastatin (10 mM) increased AMPKa-Thr 172 phosphorylation via LKB1-Ser 428 phosphorylation [5, 8] . However, in our study, simvastatin (unlike AICAR) did not cause LKB1-Ser 428 phosphorylation of porcine coronary artery suggesting that simvastatin-induced AMPKaThr 172 phosphorylation is mediated via a LKB1-Ser 428 phosphorylation-independent pathway.
Apart from LKB1, AMPK is activated/phosphorylated by Ca 2+ /calmodulin-dependent kinase kinase (CaMKK) [48] Simvastatin inhibited Ca 2+ release from intracellular stores of smooth muscle cells [50, 51] . AMPK is regulated negatively by serine/threonine phosphatase(s) e.g. PP2A [46] , and in rat's liver HMG-CoA reductase is associated with PP2A [45] . Our results clearly illustrate that simvastatin-induced PP2A-Tyr 307 phosphorylation (i.e. inactivation) [58] The biochemical existence of cytochrome P450 (CYP450) 3A4 was demonstrated in porcine coronary artery and human left internal mammary artery, and the possible local enzymatic conversion of simvastatin into simvastatin Na + by CYP450 3A4 [61] was considered. However, ketoconazole (a selective CYP450 3A4 inhibitor) failed to modify simvastatin-induced increase in pAMPKa-Thr 172 and p-PP2A-Tyr 307 expression refuted the possibility of local bio-transformation of simvastatin. Thus, our results strengthen the conclusion on the involvement of simvastatin, but not simvastatin Na + , in inhibiting vascular K ATP channel openings.
In (Figure 10 ).
